Description
Properties:
Zolmitriptan is a selective 5 – hydroxytryptamine (5HT1) receptor serotonin. It’s well
absorbed after oral administration with peak plasma concentrations occurring in 2 hours
and mean elimination half-life of 3 hours. The therapeutic activity of Zolmitriptan for the
treatment of migraine headache can be attributed to the agonist effects at the (5HT1)
receptors on intracranial blood vessels and sensory nerves of the trigeminal system which
results in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide
release.
No accumulation occurred on multiple dosing and food has no significant effect on the
bioavailability of Zolmitriptan.
Indications:
Antimigra is indicated for acute treatment of migraine attack with or without aura in adults. Contra-indications:
- Patients with ischemic heart disease (angina pectoris, history of myocardial infarction or patients who have coronary artery vasospasm including prinzmetal angina and uncontrolled hypertension
- Patients who are hypertensive to Zolmitriptan
- Pregnancy
Side-effects:
Antimigra is generally well tolerated. Most side-effects were mild and transient and didn’t lead to long-lasting effects. These include sensation of tingling, heaviness, tightness of any part of the body (chest, throat), drowsiness, dry mouth, myalgia, hypertension, and rarely tachycardia and arrhythmias.
Precautions:
- Antimigra should not be used for prophylaxis of migraine.
- Antimigra should only be used where a clear diagnosis of migraine has been established.
- Patients, who have experienced signs or symptoms suggestive of angina following dosing should be evaluated for the presence of coronary artery disease before receiving additional doses of Antimigra. They should be also monitored electrocardiographically if dosing is resumed and similar symptoms recur.
- Antimigra should be used with caution in patients with impaired hepatic function.
- Caution should be exercised when Anitmigra is administrated to a nursing mother.
Drug Interactions:
- Use of ergotamine or ergot-type containing medications (dihydroergotamine or methysergide) and Antimigra within 24 hours ofeach other should be avoided.
- Concomitant use of other 5-HT1 agonists within 24 hours of Antimigra treatment is not recommended.
- The use of Antimigra in patients receiving MAO-A inhibitors is contraindicated.
- Selective serotonin reuptake inhibitors (SSRIs) e.g., flouxetine and fluvoxamine cause weakness and in coordination when coadministrated with Antimigra.
- Cimetidine increases the plasma concentrations of Antimigra.
Dosage and Administration:
If a patient does not respond to the first dose of Antimigra, the diagnosis of migraine headache should be reconsidered before administration of a second dose. Doses: 2.5mg as soon as possible after onset and it should be repeated after 2 hours if migraine persists or recurs (increase to 5mg for subsequent attacks in patients not achieving satisfactory relief with 2.5mg dose. Maximum dose is 15mg in 24 hours.
Presentation:
A box of 20 F.C. tablets 2.5mg.
